-
RWE Alliance Supports Califf Nomination, Urges Continued Focus at FDA on Advancing Use of Real-World Evidence to Benefit Patients
RWE Alliance Supports Califf Nomination, Urges Continued Focus at FDA on Advancing Use of Real-World Evidence to Benefit Patients
Share
WASHINGTON--(BUSINESS WIRE)--The RWE Alliance supports the nomination of Dr. Robert Califf to serve as Commissioner of the U.S. Food and Drug Administration (FDA).
As a former FDA Commissioner and the founder of the Duke Clinical Research Institute, Dr. Califf is a leader in advancing innovative clinical trial designs and the use of real-world data and evidence to inform regulatory decision making. It is crucial to have an FDA Commissioner that understands the role real-world data and evidence play in improving patients’ lives.
Contacts
For Media Inquiries:
Morgan Schreurs
info@rwealliance.org
More News From RWE Alliance
Five Leading Real-World Data and Analytics Organizations Join the RWE Alliance, Doubling Membership
WASHINGTON--(BUSINESS WIRE)--The RWE Alliance is pleased to announce the addition of five new members—ConcertAI, OM1, Syneos Health, Verana Health, and Verily—to continue to advance policies to support regulatory use of real-world evidence (RWE). The RWE Alliance is a policy and advocacy coalition of real-world data (RWD) and analytics organizations with a common interest in harnessing the power of RWE to inform regulatory decision making to improve patients’ lives. The founding members of the...
RWE Alliance Submits Comments on All Four Recent FDA RWE Guidances, Looks Toward Further Engagement to Advance Use of RWE to Benefit Patients
WASHINGTON--(BUSINESS WIRE)--Today, the RWE Alliance submitted a substantial comment letter in response to the U.S. Food and Drug Administration’s (FDA) recent draft guidance, “Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products.” The RWE Alliance commends the Agency for recently issuing four substantive draft guidances on key real-world data and evidence (RWD/E) topics as part of the Agency’s RWE Program,...
RWE Alliance Submits Comments on FDA’s RWE Draft Guidance, Highlights Recommendations for Agency’s RWE Program and RWE Derived from EHR/Claims Data
WASHINGTON--(BUSINESS WIRE)--Today, the RWE Alliance submitted a substantial comment letter in response to the U.S. Food and Drug Administration (FDA) draft guidance on using electronic health records (EHRs) and medical claims data to support regulatory decision making across therapeutic areas. The RWE Alliance commends the Agency for providing this draft guidance. The RWE Alliance is committed to identifying methods that can enhance confidence in RWE study results and facilitate the integratio...